Rhythm Pharmaceuticals — Corporate Update (November 2025)

6 slides from Rhythm Pharmaceuticals's corporate update, Nov 7, 2025

Slide 2: On Today's Call
® 2 On Today’s Call • David Connolly, VP, Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Alicia Fiscus, SVP, Head of Regulatory • Hunter Smith, Chief Financial Officer
Slide 3: Forward-looking statements
® 3 This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-look
Slide 4: Timeline of Information Requests and Responses
® 4 Timeline of Information Requests and Responses Oct. 20 • FDA requests additional sensitivity analyses Oct. 27 • Rhythm submits response Nov. 6 • FDA notifies Rhythm that October 27th response deemed a major amendment • PDUFA goal date extended from December 20, 2025 to March 20, 2026
Slide 5: Key Secondary Endpoint 1: Proportion of Patients with BMI Reduction
® 5 Key Secondary Endpoint 1: Proportion of Adult Patients with ≥ 5% Reduction in BMI or Pediatric Patients with ≥0.2 BMI Z-Score Reduction January 1 Birth Date July 1 Birth Date Statistic Primary Analysis N=120 Sensitivity Analysis N=142 Sensitivity Analysis N=120 Sensitivity Analysis N=142 Setmela
Slide 6: Questions
® 6 Questions